11%. 9-11 It occurs more frequently in patients with the M5 FAB subtype and in infants with AML, the incidences being 31 and 46%, respectively.
Summary:
11%. 9-11 It occurs more frequently in patients with the M5 FAB subtype and in infants with AML, the incidences being 31 and 46%, respectively.
12-13

Leukemia cutis (LC) is a rare feature of acute myeloblastic leukemia (AML). Little information is available
Few studies have evaluated the outcome of patients with LC. The largest published series describes 18 patients with regarding its prognostic influence on post-transplant outcome. In our institution, 202 patients with AML AML and LC who were treated with conventional therapy and who experienced a high incidence of serial skin received an allogeneic HLA-identical marrow transplant from related donors between March 1982 and January relapses, suggesting that skin could provide a sanctuary site for leukemic cells. 14 While patients with acute myeloblastic 1994. Thirteen patients had prior leukemic involvement of the skin (leukemia cutis or LC group) while 189 or lymphoblastic leukemia with prior involvement of extramedullary sites such as CNS or testis treated with BMT patients did not (non-LC group). There was a higher incidence of patients with the M4-M5 FAB subtypes in have been reported to have an increased risk of extramedullary relapse post-transplantation, 15, 16 the outcome of the LC group (83%) as compared to the non-LC group (33%). In addition, the percentage of patients transpatients with a history of LC treated with marrow transplantation has not been described previously. planted in relapse was also higher in the LC group (69 vs 15%). While there were no differences observed in
We report a single institution retrospective analysis of 13 patients with AML and LC who underwent allogeneic the rates of relapse post-transplant in the LC and non-LC groups when matched for stage of disease at trans-BMT at Memorial Sloan-Kettering Cancer Center (MSKCC). The overall relapse rates and sites of relapse plant, the sites of relapse differed markedly. Five of six relapses in the LC group involved extramedullary sites that occurred in this group were compared with those observed in 189 consecutive patients with AML without as compared to only six of 38 relapses in the non-LC group (P = 0.002), with a 6-year probability of extramed-LC who were treated with allogeneic BMT during the same time period. ullary relapse of 38.5% in the LC group as compared to 3.9% in the non-LC group. This increased probability of extramedullary relapse was independent of the FAB morphology (50 vs 2% for patients with the M4-M5 subPatients and methods types in the LC and the non-LC group respectively) and of disease status at the time of transplant. Moreover, Patient groups were drawn from a series of 202 consecutive adults and children who received HLA-matched related only three relapses post-transplant involved the skin, all of which were in the LC group, with a probability of bone marrow transplants for the treatment of AML between March 1982 and January 1994. Of these, 13 had a history skin relapse of 23 one leukemic recurrence in the skin before transplant. Four In the LC group, 11 of 13 patients received HFTBI and two of these 11 patients with active skin disease received patients were transplanted in first (n = 2) or second (n = 2) complete remission (CR), and nine were transplanted in an additional 400 cGy whole skin electron boost. Following HFTBI, patients were treated with cyclophosphamide relapse. Among the nine patients transplanted in relapse, four were in bone marrow relapse with no skin involve-(60 mg/kg/day × 2) alone in six cases, thiotepa (5 mg/kg/day × 2) and cyclophosphamide in three cases as ment, three were in marrow remission but with skin disease, and two patients had both marrow and skin involvement at previously described, 19 thiotepa and etoposide or aziridinylbenzoquinone (AZQ) and cyclophosphamide in two cases. the time of BMT. The mean age at the time of BMT for the LC group was 26.1 ± 4 years (range 1-44 years).
The two patients who did not receive TBI were conditioned with busulfan and cyclophosphamide in association with For the 189 patients in the non-LC group, the mean WBC count at diagnosis was 31.2 ± 7, not significantly different high-dose cytarabine in one patient and with a radio-iodinated anti-CD33 monoclonal antibody ( 131 I-M195) in the from that of the LC group. The proportion of patients with the M4-M5 FAB subtypes, however, was lower (33 vs other, as previously described. 20 Six patients received a T cell-depleted marrow graft for the prevention of graft-ver-83%, P Ͻ 0.001). The proportion of patients transplanted in CR was also higher than that of patients in the LC group sus-host disease (GVHD) as previously described. 21, 22 For the seven remaining patients, GVHD prophylaxis consisted (85 vs 31%, P Ͻ 0.001). The mean age at BMT was comparable to that of the LC group. of different combinations of cyclosporin A, methotrexate and steroids as specified in the protocols used at our institution at the time of their transplants. Acute and chronic Treatment characteristics GVHD were evaluated according to standard published criteria, 23, 24 and treated with immunosuppressive therapy Patients in the LC and non-LC groups received transplants according to protocols evaluating different treatment strawhen indicated.
For the non-LC group, 175 patients (93%) received tegies for AML at specific stages of its progression. In brief, 186 patients including 11 in the LC group and 175 in the HFTBI-containing regimens with the addition of cyclophosphamide alone (n = 103), thiotepa and cyclophosphamide non-LC group received a hyperfractionated total body irradiation (HFTBI) containing regimen as previously (n = 33), etoposide and cyclophosphamide (n = 22), AZQ and cyclophosphamide (n = 14), and cytarabine and cyclodescribed. 17, 18 Patients transplanted before 1985 received 11 fractions to a total dose of 1375 cGy, and the rest phosphamide (n = 2). Seven patients received busulfan and cyclophosphamide and seven patients were treated with received 12 fractions to a total of 1500 cGy. All patients had lung shielding to reduce the dose to the lungs to 800-busulfan, cyclophosphamide and 131 I-anti-CD33. GVHD prophylaxis consisted of T cell-depleted marrow transplants 900 cGy. Overlying ribs were treated with a 600 cGy boost using high energy electrons to increase the total dose to the in 122 patients (65%); the remaining patients received unmodified grafts and pharmacologic GVHD prophylaxis chest wall to approximately 1500 cGy. Male patients also received a 400 cGy testicular boost with electrons.
with the addition of cyclosporine and/or methotrexate and/or steroids. These numbers were not significantly 160 patients in the non-LC group transplanted in primary to tertiary remission, 78 survive disease-free. The probdifferent from the LC group. ability of 5-year disease-free survival (DFS) for this larger group was 46 ± 8% and the probability of relapse at 5 years Statistical methods was 17 ± 6%. The risk of extra-medullary relapse in the non-LC patients transplanted in remission was 4.5 ± 3.6% The probability of disease-free survival (DFS) was calculated using the method of Kaplan-Meier. 25 The probwith no relapses involving the skin. Of the nine patients in the LC group transplanted in abilities of relapse, extramedullary relapse and skin relapse were estimated with the method of competing risks. 26 Disrelapse, only one survives disease-free 127 months posttransplant. In this group, three patients succumbed to transtributions of qualitative variables between two groups were compared according to the Fisher's exact test; comparisons plant-related toxicity, including interstitial pneumonia (n = 2) and pulmonary hemorrhage (n = 1). Five patients experiof continuous variables were made using the Wilcoxon rank sum test. 27 Extramedullary relapse and skin relapse were enced disease recurrence 2-5 months post-transplant. The 5-year estimated probability of relapse in this group was defined as extramedullary or skin leukemia occurring as the first site of disease recurrence or recurring simultaneously 56 ± 33%. Four of the five relapses occurred in extramedullary sites including the skin alone (n = 1), skin and marrow with disease in the marrow. Non-chloromatous liver, spleen or lymph node involvement occurring concomitantly with (n = 1), a solid tumor involving the soft tissue of the face and the left petrous bone (n = 1) and a chloroma of the a marrow relapse were not taken into consideration for the purpose of our analysis, and these patients were classified breast (n = 1). However, sites of skin relapse were different from sites identified prior to transplant. By comparison, of as relapsing in the marrow. Similarly, patients who relapsed initially in the bone marrow and then went on to develop 29 patients in the non-LC group transplanted in relapse, 13 patients recurred post-transplant with a risk of relapse of extramedullary disease were also classified as relapsing in the marrow.
48 ± 20% at 5 years, and a DFS of 16 ± 14%. There were no extramedullary relapses recorded in this group. While there were no differences observed in the rates of relapse post-transplant in the LC and non-LC groups when Results matched for stage of disease at transplant (Table 3 and Figure 1a) , five of the six relapses in the LC group involved an The outcome of the marrow transplants administered to the 13 patients with LC is detailed in Table 2 . The Kaplanextramedullary site, as compared to only six of 38 relapses observed in the non-LC group (P = 0.002). The probability Meier estimate of disease-free survival (DFS) at 5 years for this group was 23.1 ± 21%, with an overall relapse rate of of extramedullary relapse was 38.5 ± 27% for the LC group and 3.9 ± 3.2% for the non-LC group. All three relapses 46.2 ± 28% at 5 years.
As can be seen, of four patients transplanted in remission which involved the skin post-transplant occurred in the LC group with a probability of skin relapse post-transplant of in the LC group, one died of BMT-related toxicity (venoocclusive disease), one relapsed in the skin and marrow 7
23.1 ± 23% in the LC group and 0% for the non-LC patients (Figure 1b) . months post-transplant, and two patients survive diseasefree 15 and 20 months post-transplant. In comparison, of Because the proportion of patients with the M4-M5 FAB RT = radiation therapy; DX = diagnosis; Rel = relapse; CR = complete remission; (L) = localized radiation; TSEB = total skin electron beam therapy. subtypes was higher in the LC group, we also evaluated the probability of extramedullary relapse with respect to FAB subtypes. When all patients from the LC and non-LC groups were considered, the probability of extramedullary relapse was 10.2 ± 7.8% for patients with the M4-M5 FAB subtypes and 4.3 ± 4% for patients with the other subtypes. However, the risk of extramedullary relapse for patients in the LC group with the M4-M5 subtypes was 50 ± 32%, as compared to 2 ± 2% for the non-LC patients with the M4-M5 subtypes.
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Discussion
The purpose of this study was to analyze the relapse risk of 13 patients with AML and LC who underwent an allogeneic marrow transplant at our institution and compare it with that of 189 consecutive patients with AML but without a history of LC treated similarly at our institution during the same time period. In this series, the percentage of patients transplanted in remission in the non-LC group was higher than in the LC group. When patients were matched for stage of disease at transplant, a previous history of LC did not influence the overall relapse rate or disease-free survival after BMT, but was associated with a remarkable propensity for relapses in extramedullary sites. This observation suggests that patients with LC do not have disease that is more aggressive than that of other patients with AML, but that the clinical expression of their disease after BMT is different.
In one series of 18 patients with AML and LC treated with chemotherapy alone or with chemotherapy and skin irradiation, 14 eight patients had clinically and/or pathologically documented extramedullary leukemia in additional sites such as CNS, breast, retina, gallbladder, soft tissue or pleura at some time during their clinical course. Among 10 patients with skin involvement at the time of diagnosis, six experienced a relapse involving the skin (skin alone, n = 5; skin and bone marrow, n = 1). In a study of 29 infants achieved a complete remission but seven relapsed sub-sequently. None of these relapses occurred in the skin, but skin irradiation, none experienced a subsequent skin relapse. This suggests that adequate control of skin disease four involved the CNS.
The propensity of AML and LC to relapse in extramedulcan be achieved with systemic chemotherapy. Modification of cytoreductive regimens to include agents which may betlary sites after BMT may reflect unique biological properties of these leukemic cells. Although the molecular basis ter penetrate extramedullary sites may improve transplant results. for the homing of hematopoietic cells to the bone marrow is not completely understood, several factors including
In conclusion, our study suggests that patients with AML receiving allogeneic marrow transplants who have a history expression of certain integrins have been shown to contribute to this process. 28 Recently, reduced expression of of skin involvement differ markedly from other patients with AML transplanted at comparable stages of disease in adhesion molecules on leukemic cells has been described in patients with CML 29, 30 and CLL. 31 These abnormalities their unique propensity to relapse in extramedullary sites. Further investigations are needed to understand the biologihave been postulated to alter the homing of leukemic cells and to contribute to their independence of stromal cell supcal basis of this clinical feature and, thereby, to develop better strategies to either eradicate residual extramedullary port. Given their unusual propensity to seed and proliferate outside the marrow microenvironment, leukemic cells from sites of leukemia growth or prevent reseeding of leukemic cells in sites protected from the effector cells derived from patients with forms of AML associated with LC may exhibit the converse, namely an enhanced expression of a marrow allograft, that potentiate leukemic resistance. adhesion molecules and/or a more stringent dependence on specific extramedullary microenvironmental influences for their growth and proliferation. Of particular interest in this
